✦ LIBER ✦
30 Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial
✍ Scribed by Reck, M.; Mellemgaard, A.; Douillard, J.-Y.; Orlov, S.; Krzakowski, M.; von Pawel, J.; Gottfried, M.; Bondarenko, I.; Liao, M.; Barrueco, J.; Gaschler-Markefski, B.; Kaiser, R.; Novello, S.
- Book ID
- 122803981
- Publisher
- Elsevier Science
- Year
- 2014
- Tongue
- English
- Weight
- 48 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.